With US measles cases nearing 3,900 this year and Pennsylvania reporting its fifth measles-related death, here is a review of how the virus spreads, how it is prevented and managed, and what severe disease looks like.
|Videos|August 21, 2020
Evaluating Age Based Coronavirus Strategies With Martin Kulldorff
Author(s)Grant M. Gallagher
Martin Kulldorff, PhD, explains how an age-based focus for COVID-19 mitigation might better protect both older people and younger people with comorbidities.
Advertisement
Martin Kulldorff, PhD, is a respected biostatistician in the Division of Pharmacoepidemiology and Pharmacoeconomics at the Brigham and Women’s Hospital + Harvard Medical School. He has long been working in infectious disease outbreaks, detection of new disease outbreaks, and developing novel epidemiological methods.
He has developed new sequential statistical methods for near real-time post-market drug and vaccine safety surveillance, where the purpose is to use weekly, monthly or other frequent data feeds to find potential safety problems as soon as possible.
As a biostatistician, Dr. Kulldorff also does collaborative and consulting work with epidemiologists and clinicians, using a wide variety of study designs and methods for many different types of diseases. Dr. Kulldorff received his bachelor’s degree in mathematical statistics from Umeå University in Sweden, and his doctorate in operations research from Cornell University.
[Bio courtesy of Harvard Medical School]
Related Coverage: Raj Bhopal Full Interview: COVID-19 Zugzwang | ContagionLive
Advertisement
Related to this article
Vaxcyte's 31-valent pneumococcal conjugate vaccine candidate met every prespecified primary immunogenicity and safety endpoint against PCV20 and PCV21 in the OPUS-1 trial of 4,047 US adults.
Irkutsk anti-plague institute death prompts quarantines and conflicting official accounts.
A laboratory technician at a Siberian anti-plague institute has died of pneumonia of unknown cause, prompting quarantines and contact monitoring while Russian officials stop short of confirming plague.
A study finding clesrovimab comparable to palivizumab in protecting at-risk infants in their first RSV season was extended to demonstrate clesrovimab effective and well-tolerated when administered in their second season.
Lori Handy, MD, provides guidance in these areas including presentation before rash onset, when patients should be considered for the inpatient setting, and what treatment looks like.
Jason Pogue, PharmD, BCPS, BCIDP, contextualizes preliminary data looking at this trial and other extended-spectrum beta-lactamase (ESBL) studies, which reopens the debate around carbapenem-sparing treatment options.
In the phase 3 LIBERTY study, the investigational monoclonal antibody, VYD2311, had significantly fewer adverse events than an mRNA COVID-19 vaccine, and it did not blunt vaccine-induced neutralizing titers when the two were given together.